PD36-12 STIMWAVE® FOR PUDENDAL NEURALGIA

Abstract

You have accessJournal of UrologyUrodynamics/Lower Urinary Tract Dysfunction/Female Pelvic Medicine: Neurogenic Voiding Dysfunction (PD36)1 Sep 2021PD36-12 STIMWAVE® FOR PUDENDAL NEURALGIA Ly Hoang Roberts, Annah Vollstedt, Josh Volin, Teresa McCartney, and Kenneth Peters Ly Hoang RobertsLy Hoang Roberts More articles by this author , Annah VollstedtAnnah Vollstedt More articles by this author , Josh VolinJosh Volin More articles by this author , Teresa McCartneyTeresa McCartney More articles by this author , and Kenneth PetersKenneth Peters More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002040.12AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: In patients with pudendal neuralgia refractory to traditional therapies, prior studies have shown efficacy in chronic stimulation with Interstim® (Medtronic, Inc., Minneapolis, MN). This study reports on a wireless system to power an implanted lead at the pudendal nerve, StimWave®, to treat pudendal neuralgia. METHODS: Retrospective chart review identified patients with a lead placed at the pudendal nerve for neuralgia and powered wirelessly. Clinical outcomes were assessed at post-operative visits and phone calls. Administered non-validated follow-up questionnaire evaluated the GRA, percentage of pain improvement, satisfaction with device, and initial and current settings of the device (hours/day of stimulation). RESULTS: Thirteen patients had the StimWave® lead placed at the pudendal nerve, 12 (92%) female and 1 (7.6%) male. Mean age was 50 years (range: 20-58). Failed prior therapies include medical therapy (100%), pelvic floor physical therapy (PFPT) (92%), pudendal nerve blocks (85%), pelvic floor muscle trigger point injections (69%), neuromodulation (30.7%), or surgeries for urogenital pain (23.1%). After the trial period, 10/13 (76.9%) had >50% improvement in pain with 6/13 (46.1%) reporting 100% pain improvement. Nine underwent permanent lead placement. At last post-operative visit (range 6-83 d), 4/9 patients reported >50% pain improvement. Seven patients reached for phone calls (8-734 d) reported symptoms to be "markedly improved" (n=2; 28.6%), "moderately improved" (n =4; 57.1%,), or "slightly improved" (n=1; 14.3%). Over half (5/7) reported complications including lead migration (n=2), broken wire (n=1) or non-functioning antenna (n=2). CONCLUSIONS: Complex patients with refractory pudendal neuralgia may benefit from pudendal nerve stimulation via StimWave. Source of Funding: None © 2021 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue Supplement 3September 2021Page: e600-e600 Advertisement Copyright & Permissions© 2021 by American Urological Association Education and Research, Inc.MetricsAuthor Information Ly Hoang Roberts More articles by this author Annah Vollstedt More articles by this author Josh Volin More articles by this author Teresa McCartney More articles by this author Kenneth Peters More articles by this author Expand All Advertisement Loading ...